Inhibikase Therapeutics, Inc. (IKT) is a biotechnology company focused on developing novel therapies for neurodegenerative diseases, including Parkinson’s disease and other related disorders. The company’s key product is IkT-148009, a small molecule drug that targets a protein called alpha-synuclein, which is believed to play a critical role in the progression of Parkinson’s disease and similar […]